eight patients who had a stable or partial response, suggesting that, in addition to causing sclerosis of bone, APD may have an antitumour effect. Factors released from tumours stimulate osteoblastic activity3 and osteolysis mediated by osteoclasts.4 APD is a potent inhibitor of osteoclast function, and such inhibition combined with the osteoblastic factors produced by tumour cells may explain the bony sclerosis seen in this study.
Following the observation that prostaglandin E1, dilates the ductus arteriosus in fetal and neonatal animals, indomethacin-a potent inhibitor of prostaglandin synthesis-has been used for some years as an alternative to surgical ligation of the patent ductus arteriosus in premature infants with cardiac failure. ' Giving the drug by mouth has been associated with variable absorption and local effects in the gastrointestinal tract.2 An intravenous formulation was developed to ensure bioavailability, and this report concerns the adverse event profile in 2482 premature infants who received intravenous indomethacin (Indocid PDA).
Methods and results
Since 1980, 2482 preterm neonates in the United Kingdom have received intravenous indomethacin (recommended dosage 0-2 mg/kg intravenously with second and third doses given at 12-24 hour intervals if required) on a named patient or humanitarian basis. All supplies were accompanied by a request to report any adverse events to Merck Sharp and Dohme forthwith (cases not resulting in a report were not followed up). Treatment was contraindicated in infants with proved or suspected infections; evidence of necrotising enterocolitis; gastrointestinal bleeding; intraventricular haemorrhage; coagulation defects; and appreciable impairment of renal function.
Reports of adverse events in 146 neonates (6%) were reviewed; of these, 73 (3% of total) were rated as being possibly, probably, or definitely related to the drug treatment by the reporting physician. The table gives details of the adverse events reported. None of the 61 deaths reported were considered by the reporting physicians to be drug related. In three cases in which infants had other life threatening conditions from birth the effect of indomethacin on renal function might have contributed to the death. The cases of renal impairment observed were not usually sustained or serious, but in cases of pre-existing renal impairment (when indomethacin is contraindicated) treatment may provoke severe deterioration. Increased creatinine concentrations and hyponatraemia were reported, but both these and renal function returned to normal on closure of the patent ductus arteriosus or cessation of drug treatment. The reported instances of gastrointestinal haemorrhage were generally detected by nasogastric aspiration two to three days after administration of indomethacin, and most resolved within the next few days with no reported complications. 
Comment
The rate of successful closure of a patent ductus arteriosus with oral indomethacin has been highly variable (18-85%)' but appears to be less variable with intravenous treatment (79-91%).2 The best responses are achieved when neonates are treated in the first two weeks of life.
A review of indomethacin in the treatment of patent ductus arteriosus lists as the most important adverse effects transient impairment of renal function and decreased platelet function with possible clinical bleeding, including gastrointestinal and intraventricular haemorrhage.4 Our findings in a large series of patients identified changes in renal function with associated electrolyte imbalance and gastrointestinal bleeding as the most common drug related effects. Necrotising enterocolitis and intraventricular haemorrhage were also prominent, although the haemorrhage was not often considered by the physician to be related to treatment. The relation between drug administration and necrotising enterocolitis and intraventricular haemorrhage is difficult to assess as preterm infants with patent ductus arteriosus are predisposed to these conditions, and studies have failed to detect an enhanced risk with indomethacin treatment.I
In conclusion, these data on 2482 preterm infants treated with intravenous indomethacin indicate that the incidence of adverse events is low. The commonest unwanted effects were transient impairment of renal function and gastrointestinal bleeding, which resolved on withdrawal of the drug. The efficacy of intravenous indomethacin in patent ductus arteriosus is well docu-BMJ VOLUME 297
24 SEPTEMBER 1988 mented,3 reflecting the reliable bioavailability with this route. Although direct comparison with oral indomethacin has not been undertaken, intravenous indomethacin appears to be at least as well tolerated and should be preferred for the treatment of patent ductus arteriosus. 
Since Victorian times illegitimate babies have been known to have a reduced chance of survival. Traditional arguments relating to poverty arid lack of access to medical care became less relevant with the advent of the welfare state, yet the difference persists. The exact cause is unclear but must lie within the plethora of circumstances classed as social. The rising illegitimacy rate may have contributed to the recent rise in postneonatal mortality in the United Kingdom. Since 1975 there has been a consistent increase (from 9% to 19%) in the proportion of illegitimate live births in England and Wales. Sixty five per cent of all babies born to mothers aged under 20 are now illegitimate. Many of these mothers live in inner cities, and this trend, which does not seem to be related to failure of contraception, may have serious implications for the NHS.
This study found that legitimate babies born to young mothers are also at increased risk ofpostneonatal death. This finding conflicts with data from a Swedish study of the sudden infant death syndrome,5 but the number of married mothers under 20 in that study was small and the incidence of the syndrome in Sweden subsequently rose. The increased risk of postneonatal death among babies of young mothers (married or not) may be due to lack of maternal skills or support; perhaps the educational priorities for teenagers should be reappraised.
